Survodutide
$110.99
10mg
Survodutide (BI 456906) is an investigational peptide studied for its activity at the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R). It is a modified peptide designed for longer duration of action and has been evaluated in clinical research related to metabolic and endocrine signaling pathways.
Usage Disclaimer: Research Use Only. This product is intended strictly for laboratory research and in-vitro studies. It is not for human or animal consumption, medical use, or diagnostic purposes. Any unauthorized use of this product is strictly prohibited.
FDA Compliance: FDA Notice. The statements made regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Research Studies
Phase 2 Obesity Trial Without Diabetes (2024)
Human | 0.6-4.8mg weekly | 46 weeks | Up to 14.9% weight loss
In 387 participants with BMI ≥27 kg/m² without diabetes, survodutide 4.8mg achieved mean 14.9% weight loss vs 2.8% placebo. 83% achieved ≥5% weight loss, 69% achieved ≥10%, and 55% achieved ≥15% weight loss.
Phase 2 MASH and Fibrosis Trial (2024)
Human | 2.4-6.0mg weekly | 48 weeks | 47-62% MASH improvement
In 293 participants with biopsy-confirmed MASH and fibrosis F1-F3, survodutide improved MASH without worsening fibrosis in 47% (2.4mg), 62% (4.8mg), and 43% (6.0mg) vs 14% placebo. Liver fat reduction ≥30% occurred in 63-67% of treated patients.
Phase 2 Type 2 Diabetes Trial (2023)
Human | 0.3-2.7mg weekly | 16 weeks | Superior to semaglutide
Head-to-head comparison showed survodutide achieved greater weight loss than semaglutide 1.0mg after 16 weeks (-8.7% vs -5.3%). HbA1c reductions were dose-dependent, reaching -1.6% with highest doses.
Pair your peptide order with bacteriostatic water for proper reconstitution and storage. Adding it now ensures you have everything you need when your order arrives.
Avoid delays and complete your setup in one shipment.
